3 small cap ASX healthcare shares to watch closely in the 2020s

Here’s why I think Volpara Health Technologies Ltd (ASX:VHT) and these ASX small cap healthcare shares are worth watching…
The post 3 small cap ASX healthcare shares to watch closely in the 2020s appeared first on Motley Fool Australia. –

Digitised heart rate and share price chart with man on ipad in background signifying Hydrix share price

If you’re interested in gaining exposure to the small cap side of the market, I think it could be worth looking for options in the healthcare sector.

In this sector there are a number of companies that are benefiting from favourable tailwinds and have the potential to grow materially in the future.

Three small cap ASX healthcare shares to watch are listed below:

Mach7 Technologies Ltd (ASX: M7T)

Mach7 is a medical imaging data management solutions provider which uses software to create a clear and complete view of the patient. The company’s software helps to inform diagnosis, reduce care delivery delays and costs, and, importantly, improve patient outcomes. It recently expanded its offering via the acquisition of enterprise image viewing technology company Client Outlook. Combined, Mach7 now has a total addressable market of US$2.75 billion.

Medadvisor Ltd (ASX: MDR)

Medadvisor is a software systems developer with a focus on personal medication adherence. It offers an app that connects to pharmacy dispensing systems and has been designed to ensure correct and reliable medication use. In Australia it has connected over one million users through nearly 60% of Australian pharmacies and a network of thousands of GPs. Outside Australia, the company has growing operations in the United States, Asia, and UK markets.

Volpara Health Technologies Ltd (ASX: VHT)

Volpara uses artificial intelligence imaging algorithms to assist with the early detection of breast cancer. At the last count, its market share in the United States had grown to 27% of women screened for breast cancer. The company also advised that the annual revenue per user (ARPU) within its US breast cancer operations stood at approximately NZ$1.70 (US$1.09). However, thanks to the expansion of its product suite, during the second quarter the company has been seeing quotes with ARPU rising up to US$8.00. This is a huge step forward and validates management’s belief that its whole software platform will command ARPU of US$10.00.

Man who said buy Kogan shares at $3.63 says buy these 3 ASX stocks now

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

In this FREE STOCK REPORT, Scott just revealed what he believes are the 3 ASX stocks for the post COVID world that investors should buy right now while they still can. These stocks are trading at dirt-cheap prices and Scott thinks these could really go gangbusters as we move into ‘the new normal’.

Find out the names of our 3 Post COVID Stocks – For FREE!

*Returns as of 6/8/2020

More reading

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of and recommends MACH7 FPO. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of MedAdvisor and VOLPARA FPO NZ. The Motley Fool Australia has recommended MACH7 FPO, MedAdvisor, and VOLPARA FPO NZ. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post 3 small cap ASX healthcare shares to watch closely in the 2020s appeared first on Motley Fool Australia.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;

To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.

An active and funded account with a positive trading balance is required to continue to have access to the tools;

Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;

Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!